Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.

Autor: Ajabnoor R; Department of Pathology, University of Rochester Medical Center, Rochester, New York; Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia., Zhang G; Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio., Hu Y; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio., Gao Y; Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia., Finkelman BS; Department of Pathology, University of Rochester Medical Center, Rochester, New York., Turner BM; Department of Pathology, University of Rochester Medical Center, Rochester, New York., Yi S; Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia., Dhakal A; Department of Medicine, University of Rochester Medical Center, Rochester, New York., Audeh W; Department of Medical Affairs, Agendia Inc, Irvine, California., Li Z; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio., Li X; Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia., Hicks DG; Department of Pathology, University of Rochester Medical Center, Rochester, New York., Zhang H; Department of Pathology, University of Rochester Medical Center, Rochester, New York. Electronic address: Huina_Zhang@urmc.rochester.edu.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2024 Aug; Vol. 37 (8), pp. 100530. Date of Electronic Publication: 2024 May 27.

Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.

Autor: Navarro Sanchez JM; Department of Pathology, University of Rochester Medical Center, Rochester, NY14642, USA; Southcentral Pathology Laboratory, Wichita, KS 67214, USA., Finkelman BS; Department of Pathology, University of Rochester Medical Center, Rochester, NY14642, USA., Tyburski H; Class of 2024, University of Rochester, Rochester, NY14642, USA., Turner BM; Department of Pathology, University of Rochester Medical Center, Rochester, NY14642, USA., Moisini I; M Health Fairview Ridges Hospital, Burnsville, MN 55337, USA., Katerji H; Department of Pathology, University of Rochester Medical Center, Rochester, NY14642, USA., Varghese S; Department of Pathology, University of Rochester Medical Center, Rochester, NY14642, USA., Wang X; Department of Pathology, University of Rochester Medical Center, Rochester, NY14642, USA., Schiffhauer LM; Department of Pathology, University of Rochester Medical Center, Rochester, NY14642, USA., Chen JJ; Department of Pathology, University of Rochester Medical Center, Rochester, NY14642, USA., Hicks DG; Department of Pathology, University of Rochester Medical Center, Rochester, NY14642, USA., Zhang H; Department of Pathology, University of Rochester Medical Center, Rochester, NY14642, USA. Electronic address: Huina_Zhang@urmc.rochester.edu.

Publikováno v: Human pathology [Hum Pathol] 2024 Jun; Vol. 148, pp. 51-59. Date of Electronic Publication: 2024 May 11.

HER2 in uterine serous carcinoma: Current state and clinical perspectives.

Autor: Navarro Sanchez JM; Department of Pathology, University of Rochester Medical Center, Rochester, NY, US., Finkelman BS; Department of Pathology, University of Rochester Medical Center, Rochester, NY, US., Turner BM; Department of Pathology, University of Rochester Medical Center, Rochester, NY, US., Katerji H; Department of Pathology, University of Rochester Medical Center, Rochester, NY, US., Wang X; Department of Pathology, University of Rochester Medical Center, Rochester, NY, US., Varghese S; Department of Pathology, University of Rochester Medical Center, Rochester, NY, US., Wang T; Department of Pathology, University of Southern California, Los Angeles, CA, US., Peng Y; Department of Pathology and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, US., Hicks DG; Department of Pathology, University of Rochester Medical Center, Rochester, NY, US., Zhang H; Department of Pathology, University of Rochester Medical Center, Rochester, NY, US.

Publikováno v: American journal of clinical pathology [Am J Clin Pathol] 2023 Oct 03; Vol. 160 (4), pp. 341-351.

The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX ^® Testing.

Autor: Turner BM; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA., Finkelman BS; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA., Hicks DG; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA., Numbereye N; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA., Moisini I; M. Health Fairview Ridges, Burnsville, MN 55337, USA., Dhakal A; Department of Medical Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA., Skinner K; Department of Surgical Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA., Sanders MAG; Norton Healthcare, University of Louisville Department of Pathology, Louisville, KY 40292, USA., Wang X; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA., Shayne M; Department of Medical Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA., Schiffhauer L; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA., Katerji H; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA., Zhang H; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA.

Publikováno v: Cancers [Cancers (Basel)] 2023 Jan 31; Vol. 15 (3). Date of Electronic Publication: 2023 Jan 31.

The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas.

Autor: See SHC; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: sharlene.see@northwestern.edu., Smith SH; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Finkelman BS; Department of Pathology, University of Rochester School of Medicine, Rochester, NY, USA., LaBoy C; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Novo JE; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Siziopikou KP; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Blanco LZ Jr; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Publikováno v: Pathology, research and practice [Pathol Res Pract] 2023 Jan; Vol. 241, pp. 154299. Date of Electronic Publication: 2022 Dec 31.